

Special Issue

Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

Message from the Guest Editor

Hematopoietic stem cell transplantation (HSCT) is a critical therapeutic approach for acute myeloid leukemia (AML), offering the potential for long-term remission and cure, particularly in high-risk patients and those with relapsed or refractory disease. The aim of HSCT is to reestablish the bone marrow following intensive chemotherapy or radiation therapy, thereby eradicating the leukemia cell population. Allogeneic HSCT, which uses donor cells, is preferred due to its graft-versus-leukemia effect, where immune cells from the donor target and destroy residual leukemia cells. There are several significant challenges associated with HSCT, such as graft-versus-host disease, infections, and regimen-related toxicities that negatively impact patient outcomes. HSCT has become safer and more effective through advances in donor selection, conditioning regimens, and supportive care. The goal of current research is to optimize transplant protocols, minimize complications, and integrate novel therapies to enhance HSCT's success in treating AML, which we will examine through this Special Issue.

Guest Editor

Dr. Nidhi Jyotsana

Salk Institute for Biological Studies, Gene Expression Laboratory, 10010 N Torrey Pines Rd, La Jolla, CA 92037, USA

Deadline for manuscript submissions

closed (30 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/216233

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)